AR096459A1 - Composiciones de corticosteroides y método de fabricación - Google Patents

Composiciones de corticosteroides y método de fabricación

Info

Publication number
AR096459A1
AR096459A1 ARP140102162A ARP140102162A AR096459A1 AR 096459 A1 AR096459 A1 AR 096459A1 AR P140102162 A ARP140102162 A AR P140102162A AR P140102162 A ARP140102162 A AR P140102162A AR 096459 A1 AR096459 A1 AR 096459A1
Authority
AR
Argentina
Prior art keywords
manufacturing
corticosteroid
pharmaceutical composition
corticosteroid compositions
ester
Prior art date
Application number
ARP140102162A
Other languages
English (en)
Spanish (es)
Inventor
Lathrop Robert
Wade Osborne David
Original Assignee
Tolmar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar Inc filed Critical Tolmar Inc
Publication of AR096459A1 publication Critical patent/AR096459A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP140102162A 2013-06-03 2014-06-02 Composiciones de corticosteroides y método de fabricación AR096459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361830531P 2013-06-03 2013-06-03

Publications (1)

Publication Number Publication Date
AR096459A1 true AR096459A1 (es) 2015-12-30

Family

ID=51014660

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102162A AR096459A1 (es) 2013-06-03 2014-06-02 Composiciones de corticosteroides y método de fabricación

Country Status (9)

Country Link
EP (1) EP3003272A1 (enExample)
JP (1) JP2016520656A (enExample)
CN (1) CN105263474A (enExample)
AR (1) AR096459A1 (enExample)
AU (1) AU2014275195A1 (enExample)
CA (1) CA2912873A1 (enExample)
HK (1) HK1223300A1 (enExample)
MX (1) MX2015016603A (enExample)
WO (1) WO2014197398A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011026076A2 (en) 2009-08-31 2011-03-03 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
ITUB20153460A1 (it) 2015-09-08 2017-03-08 Novamont Spa Composizioni cosmetiche acquose contenenti esteri dell?acido pelargonico
MX391097B (es) * 2017-11-27 2025-03-21 Umecrine Cognition Ab FORMULACIÓN FARMACÉUTICA DE 3A-ETINIL-3ß-HIDROXIANDROSTAN-17-ONA OXIMA.
WO2023277616A1 (ko) * 2021-06-30 2023-01-05 주식회사 디네이쳐 중대가리풀 유래의 추출물을 포함하는 탈모기능성 조성물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1048820A (en) * 1963-05-29 1966-11-23 Merck & Co Inc Emollient compositions containing liquid fatty acid esters
US4305936A (en) * 1980-10-09 1981-12-15 Dermik Laboratories Topical corticosteroid formulations
US4863738A (en) * 1987-11-23 1989-09-05 Alza Corporation Skin permeation enhancer compositions using glycerol monooleate
US5087620A (en) * 1990-05-17 1992-02-11 Bristol-Myers Squibb Co. Controlled dermal penetration enhancement using imidazoles
JP3471840B2 (ja) * 1993-03-04 2003-12-02 日本ワイスレダリー株式会社 外用剤
US6512010B1 (en) * 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
GB9618964D0 (en) * 1996-09-11 1996-10-23 Tillotts Pharma Ag Oral composition
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
PT1194109E (pt) * 1999-06-25 2004-12-31 Durham Pharmaceuticals Ltd Formulacoes topicas compreendendo agentes de penetracao na pele e utilizacao dasmesmas
JP2001233772A (ja) * 2000-02-23 2001-08-28 Taiho Yakuhin Kogyo Kk 外用剤組成物
KR100433614B1 (ko) * 2000-06-16 2004-05-31 주식회사 태평양 친수성 또는 염의 형태로 된 약물을 함유하는 경피흡수제제
EP1648412B1 (en) * 2003-07-07 2007-11-14 Nares AB Microemulsions and its use for preventing airway diseases
PL1744760T3 (pl) * 2004-04-22 2015-04-30 Acucort Ab Kompozycja farmaceutyczna do ostrego leczenia glikokortykosteroidami
AU2005313601B2 (en) * 2004-12-09 2012-05-24 Bayer Intellectual Property Gmbh Stabilisation of glucocorticoid esters with acids
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
FR2889662B1 (fr) * 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
GB2445539A (en) * 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
RS53809B1 (sr) * 2010-06-11 2015-06-30 Leo Pharma A/S Farmaceutska kompozicija spreja za kožu koja sadrži analog vitamina d i kortikosteroid
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
CN102940594A (zh) * 2012-12-04 2013-02-27 艾能赛克机械设备(江苏)有限公司 一种头发调理剂

Also Published As

Publication number Publication date
CA2912873A1 (en) 2014-12-11
AU2014275195A1 (en) 2015-12-10
CN105263474A (zh) 2016-01-20
WO2014197398A1 (en) 2014-12-11
EP3003272A1 (en) 2016-04-13
MX2015016603A (es) 2016-07-28
JP2016520656A (ja) 2016-07-14
HK1223300A1 (zh) 2017-07-28

Similar Documents

Publication Publication Date Title
AR096459A1 (es) Composiciones de corticosteroides y método de fabricación
BR112015023629A8 (pt) Formulação de acetato de abiraterona
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
EA201590730A1 (ru) Способ и стероидная композиция для местного применения
CO2017003396A2 (es) Esteroides neuroactivos, composiciones y usos de los mismos
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
EP3260463A4 (en) Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
MX2018010902A (es) Esteroides neuroactivos, composiciones y usos de los mismos.
DOP2015000202A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
AR108073A1 (es) Composición farmacéutica de hormona esteroide, método
UA114615C2 (uk) Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
CO2017002472A2 (es) Formulación de acetato de abiraterona
EP3454840A4 (en) COMPOSED FORMULATION OF DUTASTERIDE AND TADALAFIL WITH GLYCERINE Fatty Acid Ester Derivative Or Propylene Glycol Fatty Acid Ester Derivative And Oral Capsule Formulation With It
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
MX2016000964A (es) Composiciones farmaceuticas para la administracion intraocular que comprenden un agente antibacteriano y un agente antiinflamatorio.
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
MX389866B (es) El uso de 9-cis-retinil acetato para mejorar la funcion visual de un sujeto que padece de perdida de la funcion visual originada por una deficiencia retinoide endogena de 11-cis retinal.
ECSP15022442A (es) Producto de comicronización que comprende acetato de ulipristal
PT3768241T (pt) Composição tópica compreendendo calcipotriol e dipropionato de betametasona
CL2017001077A1 (es) Composiciones farmacéuticas que comprenden lobeglitazona para administración oral
UY36948A (es) Formulaciones de corticosteroides para mantener concentraciones de corticosteroide en el líquido sinovial
MX2019013049A (es) Composicion para el cuidado del cabello que comprende compuestos de tri-esteres y esteres grasos de acido benzoico.
JP2015034162A5 (enExample)
UY34496A (es) Formulacion nasal

Legal Events

Date Code Title Description
FB Suspension of granting procedure